Results 281 to 290 of about 80,266 (330)

The new Bruton's tyrosine kinase inhibitors SPA8007 and SPA8009 reduce stemness and invasiveness of patient-derived glioblastoma tumorspheres. [PDF]

open access: yesTransl Oncol
Jo E   +19 more
europepmc   +1 more source

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. [PDF]

open access: yesBlood Adv
García-Sanz R   +15 more
europepmc   +1 more source

The diagnostic value of dual-energy CTA for visualising below the knee arteries in peripheral arterial disease: A systematic review. [PDF]

open access: yesEur J Radiol Open
Baars J   +8 more
europepmc   +1 more source

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers. [PDF]

open access: yesFront Oncol
Kluitmans DJF   +8 more
europepmc   +1 more source

Exploratory Covalent Docking of Michael-Acceptor Natural Products at Reactive Cysteines in Cancer Tyrosine Kinases. [PDF]

open access: yesInt J Mol Sci
Lobo F   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy